AZN - Ticker AI Digest

AstraZeneca PLC
13652.00 | Today -1.09%
Desk Snapshot GO VIP Login
Important AI Risk Notice

Charts, catalyst summaries, AI scores, forecasts and price context are AI-driven and can hallucinate, lag or miss market-changing information.

Not investment advice. Markets can move fast and any trade or allocation decision remains your responsibility.
AI can hallucinate. Summaries, rankings, forecasts and commentary can be wrong, incomplete or misleading.
AI-driven data only. Signals, dates, prices, sentiment and automation outputs may be delayed, estimated or stale.
Always verify externally. Confirm prices, filings, broker notes and trade setup details with independent sources before acting.
Mobile Command Deck
AstraZeneca PLC in one cleaner mobile flow.
Tap straight into the module you want. No sideways tab hunt, just a clean route into charts, news, Today’s AI, and the deeper desks.
AZN Data 2026-06-01 Preview Mode
Core Deck
Deep Dive Modules

Digested News

Today's Catalysts (AZN) 0
No same-day market news for AZN on 2026-06-01.
AI 0
No items for this category on selected date.
Acquisitions 0
No items for this category on selected date.
Agreement 0
No items for this category on selected date.
Approvals 4
AZN 06:01
AstraZeneca PLC
Imfinzi approved in US for early bladder cancer
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
AstraZenecas Imfinzi (durvalumab) in combination with Bacillus Calmette-Guérin (BCG) therapy has been approved in the US for treating BCG-naïve, high-risk non-muscle-invasive bladder cancer (NMIBC). The approval is based on positive results from the POTOMAC Phase III trial, which showed a 32% reduction in disease recurrence, progression, or death compared to BCG alone. This marks the first new therapy in over 30 years for this patient group, addressing a significant unmet need in a curative-intent setting. Regulatory submissions are under review in the EU, Japan, and other countries. Imfinzi continues to expand its indications across various cancers, reinforcing AstraZenecas leadership in immuno-oncology and oncology innovation.
Approvals
AZN 06:01
AstraZeneca PLC
Datroway approved in US for 1L triple-negative BC
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
AstraZeneca and Daiichi Sankyos Datroway (datopotamab deruxtecan) has been approved in the US for the first-line treatment of patients with metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. This approval is based on the TROPION-Breast02 Phase III trial, which demonstrated a statistically significant improvement in overall survival (OS) and progression-free survival (PFS) compared to chemotherapy. Datroway is the first TROP2-directed antibody drug conjugate to show such benefits in this patient population, offering a new standard of care beyond traditional chemotherapy. The approval follows Priority Review by the FDA and is part of Project Orbis, with ongoing reviews in other countries. Datroway has the potential to redefine the treatment landscape for metastatic TNBC, a particularly aggressive form of breast cancer with limited treatment options.
Approvals
AZN 06:06
AstraZeneca PLC
Enhertu approved in two HER2+ early BC settings
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
The U.S. FDA has approved AstraZeneca and Daiichi Sankyos Enhertu (trastuzumab deruxtecan) for two new indications in HER2-positive early breast cancer: neoadjuvant treatment before surgery and adjuvant treatment after surgery. This approval is based on positive results from the DESTINY-Breast11 and DESTINY-Breast05 Phase III trials, respectively. The neoadjuvant approval is for patients with Stage II or Stage III breast cancer, while the adjuvant approval is for patients with residual invasive disease after initial treatment. These approvals expand Enhertus role in curative-intent settings, potentially making it a new standard of care in early-stage HER2-positive breast cancer. The decision triggers a $155 million milestone payment from AstraZeneca to Daiichi Sankyo.
Approvals
AZN 06:01
AstraZeneca PLC
Baxfendy approved in the US for hypertension
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
AstraZenecas Baxfendy (baxdrostat) has been approved in the US as the first aldosterone synthase inhibitor (ASI) for treating hypertension in adults not adequately controlled by other medications. The approval is based on the BaxHTN Phase III trial, which showed a statistically significant and clinically meaningful reduction in systolic blood pressure (15.7 mmHg absolute, 9.8 mmHg placebo-adjusted for the 2mg dose). Baxfendy addresses a critical need for the 1.4 billion people worldwide with hypertension, particularly the 50% in the US who remain uncontrolled despite multiple medications. This novel treatment targets aldosterone, a hormone linked to high blood pressure and cardiovascular risks, offering a new approach to managing this leading global health issue.
Approvals
Authorisation 0
No items for this category on selected date.
Awards 0
No items for this category on selected date.
BTC 0
No items for this category on selected date.
Blockchain 0
No items for this category on selected date.
Breakthrough 0
No items for this category on selected date.
BuyBack 0
No items for this category on selected date.
Cancellations 0
No items for this category on selected date.
CashOffer 0
No items for this category on selected date.
Collaborate 0
No items for this category on selected date.
ContractWin 0
No items for this category on selected date.
Covid-19 0
No items for this category on selected date.
Deals 0
No items for this category on selected date.
Diamond 0
No items for this category on selected date.
DirectorDealing 1
AZN 14:01
AstraZeneca PLC
Director/PDMR Shareholding
Discovery 0
No items for this category on selected date.
Exceeded 0
No items for this category on selected date.
FCA 0
No items for this category on selected date.
FDA 1
AZN 06:01
AstraZeneca PLC
US FDA decision date on camizestrant extended
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
The US FDA has extended the decision date for AstraZenecas camizestrant in combination with CDK4/6 inhibitors for first-line treatment of HR-positive, HER2-negative advanced breast cancer with ESR1 mutations. This extension allows for the review of additional data, including ctDNA clearance linked to long-term efficacy, to be presented at ASCO 2026. The decision follows the SERENA-6 Phase III trial, which showed positive results but lacked a majority vote from the FDAs Oncologic Drugs Advisory Committee. Camizestrant is already approved in the UAE and Saudi Arabia, with regulatory reviews ongoing in other countries. AstraZeneca remains committed to advancing breast cancer treatments, aiming to improve outcomes and address unmet needs in this disease area.
FDA
Grants 0
No items for this category on selected date.
InvestmentPlan 0
No items for this category on selected date.
JV 0
No items for this category on selected date.
Launch 0
No items for this category on selected date.
Litigation 0
No items for this category on selected date.
NewContract 0
No items for this category on selected date.
Offers 0
No items for this category on selected date.
Offtake 0
No items for this category on selected date.
Orders 0
No items for this category on selected date.
Partner 0
No items for this category on selected date.
Patents 0
No items for this category on selected date.
Placing 0
No items for this category on selected date.
Positive 0
No items for this category on selected date.
Proposals 0
No items for this category on selected date.
Reports 0
No items for this category on selected date.
Results 0
No items for this category on selected date.
Significant 0
No items for this category on selected date.
Speculation 0
No items for this category on selected date.
Strategic 0
No items for this category on selected date.
Suspension 0
No items for this category on selected date.
TR1 0
No items for this category on selected date.
Takeover 0
No items for this category on selected date.
Understanding 0
No items for this category on selected date.
Updates 0
No items for this category on selected date.
Vaccine 0
No items for this category on selected date.
Wins 0
No items for this category on selected date.
Worth 0
No items for this category on selected date.
All Market News (Last 30 Days) 9
AZN 06:01
AstraZeneca PLC
Imfinzi approved in US for early bladder cancer
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
AstraZenecas Imfinzi (durvalumab) in combination with Bacillus Calmette-Guérin (BCG) therapy has been approved in the US for treating BCG-naïve, high-risk non-muscle-invasive bladder cancer (NMIBC). The approval is based on positive results from the POTOMAC Phase III trial, which showed a 32% reduction in disease recurrence, progression, or death compared to BCG alone. This marks the first new therapy in over 30 years for this patient group, addressing a significant unmet need in a curative-intent setting. Regulatory submissions are under review in the EU, Japan, and other countries. Imfinzi continues to expand its indications across various cancers, reinforcing AstraZenecas leadership in immuno-oncology and oncology innovation.
Approvals
AZN 06:01
AstraZeneca PLC
US FDA decision date on camizestrant extended
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
The US FDA has extended the decision date for AstraZenecas camizestrant in combination with CDK4/6 inhibitors for first-line treatment of HR-positive, HER2-negative advanced breast cancer with ESR1 mutations. This extension allows for the review of additional data, including ctDNA clearance linked to long-term efficacy, to be presented at ASCO 2026. The decision follows the SERENA-6 Phase III trial, which showed positive results but lacked a majority vote from the FDAs Oncologic Drugs Advisory Committee. Camizestrant is already approved in the UAE and Saudi Arabia, with regulatory reviews ongoing in other countries. AstraZeneca remains committed to advancing breast cancer treatments, aiming to improve outcomes and address unmet needs in this disease area.
FDA
AZN 06:01
AstraZeneca PLC
Enhertu recommended in EU for HER2+ solid tumours
AZN 06:01
AstraZeneca PLC
Camizestrant recommended for breast cancer in EU
AZN 06:01
AstraZeneca PLC
Datroway approved in US for 1L triple-negative BC
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
AstraZeneca and Daiichi Sankyos Datroway (datopotamab deruxtecan) has been approved in the US for the first-line treatment of patients with metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. This approval is based on the TROPION-Breast02 Phase III trial, which demonstrated a statistically significant improvement in overall survival (OS) and progression-free survival (PFS) compared to chemotherapy. Datroway is the first TROP2-directed antibody drug conjugate to show such benefits in this patient population, offering a new standard of care beyond traditional chemotherapy. The approval follows Priority Review by the FDA and is part of Project Orbis, with ongoing reviews in other countries. Datroway has the potential to redefine the treatment landscape for metastatic TNBC, a particularly aggressive form of breast cancer with limited treatment options.
Approvals
AZN 14:01
AstraZeneca PLC
Director/PDMR Shareholding
AZN 06:06
AstraZeneca PLC
Enhertu approved in two HER2+ early BC settings
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
The U.S. FDA has approved AstraZeneca and Daiichi Sankyos Enhertu (trastuzumab deruxtecan) for two new indications in HER2-positive early breast cancer: neoadjuvant treatment before surgery and adjuvant treatment after surgery. This approval is based on positive results from the DESTINY-Breast11 and DESTINY-Breast05 Phase III trials, respectively. The neoadjuvant approval is for patients with Stage II or Stage III breast cancer, while the adjuvant approval is for patients with residual invasive disease after initial treatment. These approvals expand Enhertus role in curative-intent settings, potentially making it a new standard of care in early-stage HER2-positive breast cancer. The decision triggers a $155 million milestone payment from AstraZeneca to Daiichi Sankyo.
Approvals
AZN 06:01
AstraZeneca PLC
Baxfendy approved in the US for hypertension
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
AstraZenecas Baxfendy (baxdrostat) has been approved in the US as the first aldosterone synthase inhibitor (ASI) for treating hypertension in adults not adequately controlled by other medications. The approval is based on the BaxHTN Phase III trial, which showed a statistically significant and clinically meaningful reduction in systolic blood pressure (15.7 mmHg absolute, 9.8 mmHg placebo-adjusted for the 2mg dose). Baxfendy addresses a critical need for the 1.4 billion people worldwide with hypertension, particularly the 50% in the US who remain uncontrolled despite multiple medications. This novel treatment targets aldosterone, a hormone linked to high blood pressure and cardiovascular risks, offering a new approach to managing this leading global health issue.
Approvals
AZN 06:01
AstraZeneca PLC
Imfinzi + EV improves EFS & OS in bladder cancer

Today's AI

Today's AI Starts With News

Today’s AI opens with the latest catalyst tape for AZN.

No same-day headline has printed on 2026-06-01 yet, but the latest digestion still leads Today’s AI before the findings and blend stack below. Financial Forecastist remains wired into the blend.
Standby Tape Data 2026-06-01 Blend Lower Down
Read the alert tape first, then open Today’s AI findings. Use AI Expand on any card to open the AI explanation, results tables and financial forecast rows instantly.
0 Today
Front Of Desk
The live alert stack is quiet right now, but the latest digestion is still parked at the top before the findings and blend stack below.
06:01 Latest Tape Enhertu recommended in EU for HER2+ solid tumours
Single-Ticker Today's AI
AZN signal theatre built from scored market catalysts, automated AI forecasts, financial forecasting and live trigger logic.

This is the ticker-specific Today’s AI desk for AstraZeneca PLC. It compresses the live catalyst tape, bullish and bearish scoring, AI price forecasts, financial forecasting and trigger logic into one cockpit so users can judge conviction without hopping across screens.

Subscription Required Bullish vs Bearish Scoring AI + Financial Blend Buy / Sell Trigger Engine Today's AI Findings
Create Account Member Login
Subscriber Unlock
Subscribe to unlock the full AZN Today’s AI cockpit.

Subscription turns this tab into a live signal desk with today’s news findings at the top, AI plus financial blend comparisons at the bottom, buy and sell trigger logic, and the full findings ledger behind every scored row.

  • AI-scored market headlines with sentiment buckets and buzzword breakdowns.
  • Forecast leaders ranked by projected gain against current market price.
  • Advanced technical scans, AI forecast stacks, and predictive MACD inside the live stock terminal charts.
  • Single-ticker AI Crunch desks with buy or sell trigger logic and full catalyst ledgers.
  • Scored earnings shock board with predicted direction, sector pulse and catalyst narrative.
  • Fast market scan built for event-driven trading, not passive dashboards.
Subscribe to unlock the ticker-specific Today’s AI stack, sentiment gauges, AI blend stage, and the full findings ledger for AZN on 2026-06-01.

Fundamentals Matrix

Overall Fundamentals
Signal: Pending
Capital Strength
Signal: Pending
Float Liquidity
Signal: Pending
Short Pressure
Signal: Pending
Target Setup
Signal: Pending
Market Profile
Signal: Pending
Market Cap
214.0B
Enterprise Value
188.0B
Public Float
99.4
Broker Target
16466.002
Shares Out
1.6B
Long Interest
100
Short Interest
0
Exchange
LSE
Currency Code
GBX
ISIN
GB0009895292
Market
LSE - MAIN MARKET
Sector
Health Care
Float / Shares Ratio
-
Short vs Long Delta
-
EV / Market Cap
-

Financials Matrix

News And Alerts First

The alert tape opens the door for AZN, and Financial Forecastist sits just below.

No same-day alert has printed on 2026-06-01 yet, but the latest digestion is pinned here first so the forecastist view below still opens with context instead of raw numbers.
Standby Alerts Data 2026-06-01 Forecastist Below
Read the alert tape first, then move into Financial Forecastist below. Use AI Expand on any catalyst card to open the AI explanation and results tables without losing the ticker context.
0 Alerts
Front Of Desk
The live alert stack is quiet right now, but the latest digestion is still parked at the top before the forecastist read below.
06:01 Latest Alert Enhertu recommended in EU for HER2+ solid tumours
Overall Stability
Signal: Pending
Profitability
Signal: Pending
Debt & Cash
Signal: Pending
Valuation Risk
Signal: Pending
Forward Expectation
Signal: Pending
Dividend Safety
Signal: Pending
Divi Rate
2.36
Ex Divi
2026-02-19
Earnings Date
2026-02-05
Net Debt
23.9B
Cash
5.7B
EPS
4.94
Net Income
10.2B
Revenue
58.7B
Enterprise Value
188.0B
Trailing PE
27.9393
Forward PE
18.1159
Price Sales TTM
3.5416
Price Book MRQ
6.0377
EV Revenue
5.1626
EV EBITDA
15.4897
Financial Forecastist

Mixed financial engine

Revenue is accelerating +9.5% against the prior comparable period. Net margin is compressing by 1.3 pts. Net debt is building +1.1%.

Revenue +9.5% Net Income +2.8% FCF -44.5% Current Ratio 0.91x Forward Rev 16.2B
Mixed
Quarter Revenue
15.3B
+9.5%
vs prior comparable quarter
Net Margin
+20.1%
-1.3 pts
profitability pulse
Free Cash Flow
1.8B
-44.5%
cash conversion
Net Debt / EBITDA
4.6x
+1.1%
lower is cleaner
Revenue Engine

Latest quarter printed 15.3B with the top line pushing higher against the last comparable period.

Profit Stack

Net income landed at 3.1B and the margin profile is tightening. That usually tells us whether operating leverage is finally kicking in.

Balance-Sheet Pressure

Cash sits near 7.6B while net debt is 26.4B. The leverage stack is moving the wrong way.

Quarterly Revenue Runway

Actual revenue bars, consensus revenue where available, plus the terminal model path.

Profit And Cash Conversion

Net income and free cash flow moving together is usually what separates genuine improvement from noise.

Balance-Sheet Pressure

Cash, net debt and liquidity tell us whether the business is strengthening or just surviving.

Annual Power Curve

Longer-cycle revenue and net income help frame whether the company is compounding or rolling over.
Q3 2025
Consensus
14.8B
Revenue Path
2.27
EPS / Earnings
Growth cue +0.1%
Q1 2026
Consensus
14.9B
Revenue Path
2.52
EPS / Earnings
Growth cue +0.0%
Q2 2026
Consensus
15.4B
Revenue Path
2.50
EPS / Earnings
Growth cue +0.2%
Q3 2026
Consensus
16.2B
Revenue Path
2.69
EPS / Earnings
Growth cue +0.1%
FY 2026
Consensus
63.3B
Revenue Path
10.30
EPS / Earnings
Growth cue +0.1%
FY 2027
Consensus
67.1B
Revenue Path
11.62
EPS / Earnings
Growth cue +0.1%

Quarterly Statement Tape

Last 6 Quarters
Period Revenue Net Income FCF Net Debt
Q1 2026 15.3B 3.1B 1.8B 26.4B
Q4 2025 15.5B 2.3B 1.1B 23.9B
Q3 2025 15.2B 2.5B 4.4B 24.5B
Q2 2025 14.8B 2.5B 1.5B 25.8B
Q1 2025 14.0B 3.0B 3.3B 26.1B
Q4 2024 14.5B 1.5B 2.0B 24.6B

Annual Financial Power

Last 5 Years
Period Revenue Net Income EBITDA FCF
FY 2025 58.7B 10.2B 19.8B 8.7B
FY 2024 52.9B 6.9B 14.9B 7.3B
FY 2023 46.6B 6.1B 13.2B 6.6B
FY 2022 44.3B 3.3B 8.6B 7.2B
FY 2021 37.1B 109.9M 4.6B 3.8B

Structure DNA

Market Structure DNA

Yield Compounder profile with trend runway open

Price is 90.2% through the 52-week range, +2.2% vs 50DMA and +15.0% vs 200DMA. 57.3% of the register is locked by institutions and insiders, leaving 42.7% free float. Capital rhythm reads semi-annual with forward yield near 1.6% and payout around 25.8%.

Trend runway open Institutional gravity Reliable income rhythm As Of 2026-04-19
Yield Compounder
Structure Score
77.4 / 100
Yield Compounder
Trend Stack
+2.2% / +15.0%
vs 50DMA / 200DMA
52W Position
90.2%
auction position inside the yearly range
Ownership Lock
57.3%
57.3% institutions | 4.2% insiders
Pressure Pocket
42.7% free float
Vendor short-float fields were not supplied
Capital Rhythm
Semi-Annual
Yield 1.6% | payout 25.8%
Trend Runway

Implied spot is 15,118.00 with the stock +2.2% vs 50DMA and +15.0% vs 200DMA. The tape is sitting 90.2% through the 52-week range, which frames the regime as trend runway open.

Ownership Register

Institutions hold about 57.3% and insiders about 4.2%, locking roughly 57.3% of the register and leaving 42.7% in free float. That reads as institutional gravity.

Pressure Pocket

The API did not return a usable short-float field for this ticker, so the pressure score leans more on float lock and crowding than a full short ledger.

Capital Rhythm

Dividend cadence reads semi-annual with 2 event(s) in the last full year, a five-year average of 2.0, and stability score 100.0/100. Forward yield sits near 1.6% while payout is around 25.8%.

Structure Score

One-glance gauge for the current market-structure regime.

Pillar Radar

Trend, ownership, pressure, and capital rhythm mapped on one wheel.

Position And Float Balance

Shows whether the stock is extended, tightly held, or carrying capital-return support.

Dividend Cadence Tape

Historical dividend-event counts help reveal how dependable the income rhythm has been.

Dividend Cadence Ledger

Semi-Annual
Year Dividend Count Context
2026 1 Current partial year
2025 2 Full year
2024 2 Full year
2023 2 Full year
2022 2 Full year
2021 2 Full year
2020 2 Full year
2019 2 Full year

Structure Facts

Live Snapshot
Implied Spot
15,118.00
derived from market cap / shares
52W High
15,730.38
upper auction edge
52W Low
9,485.68
lower auction edge
Beta
0.28
volatility character
Shares Out
1.6B
fully diluted count
Shares Float
1.5B
tradable register
Shares Short
0
borrowed stock
Short Ratio
0.0x
days-to-cover style read
Ex-Dividend
2026-02-19
-59 day(s) to ex-date
Dividend Pay
-
payment date not supplied
Last Split
-
split date not supplied

Capital Radar

Capital Regime
—
Building signal blend...
Smart Money Tilt
—
Public vs institutions
Target Conviction
—
Broker coverage pulse
Insider Pressure
—
Director + TR1 flow
Last Held Position
-
Public Hands
-
Institutions
4.9735
Institutions As Of
2025-12-04
Avg Broker Target
14880.5
Upside Vs Price
9.0%
Purchase Director Dealing
5
Sale Director Dealing
2
Purchase TR1
3
Sale TR1
3
Broker Coverage Rows
40
Institution Holders Tracked
1
Public Vs Institutional Ownership (3D)
Top Institution Holders (Latest Per Holder)
Director Dealing Sentiment Flow
Broker Target Bias
Signal: Pending
Capital Momentum Matrix
Broker Targets Vs Price
Aggregated Institution Weight By Holder

Short Data - Last 30 Days

Nexus Pulse Engine

Overall Buy/Sell/Hold
Signal: Pending
Technical Composite
Signal: Pending
Financial Composite
Signal: Pending
Fundamental Composite
Signal: Pending
Short Pressure
Signal: Pending
Momentum Bias
Signal: Pending

Volatility Lab

ATR(14)
Realized Vol (20d)
Volume Spike Z

AI Charts

News And Alerts First

Start with the latest alert tape for AZN, then drop into AI Charts below.

No same-day headline has printed on 2026-06-01 yet, but the latest digestion is parked at the top before the chart workspace below so users can frame price, AI targets and structure from the latest tape.
Standby Tape Data 2026-06-01 AI Charts Below
Read the alert tape first, then move into AI Charts below. Use AI Expand on any catalyst card to open the AI explanation and results tables instantly.
0 Today
Catalyst Pulse
The live alert stack is quiet right now, but the latest digestion is still parked at the top before the chart read below.
06:01 Latest Tape Enhertu recommended in EU for HER2+ solid tumours
AI Charts Studio
AZN Price History
Live structure, automated forecasts, technical overlays and catalyst beacons in one chart workspace.
30 Day View Window 30D Data 2026-06-01 Open Preview Studio Brief
Chart Intelligence Suite
Swipe the timeframe, call the overlays, and keep the AI signal stack fused into one chart cockpit.
The mobile chart console is now framed as one connected surface so forecasting, structure, catalyst beacons and chart tools all sit inside the price workspace.

Automated signalling scans momentum shifts, crossovers and volatility breaks in real time. Automated AI forecasts map best, average and worst simulation paths forward, predictive MACD extends the momentum story, and catalyst beacons pin market-moving headlines directly onto price action so users can connect news, signals and structure without leaving the chart.

Automated Signalling Automated AI Forecasts Predictive MACD Catalyst Beacons Live Price Structure
Desk Snapshot Member Login
Indicators0
Technicals0
AI Forecast 8.12%
RSI Gauge
Price Change
AI Forecast